Multiple myeloma is a malignant plasma cell disorder characterized by clonal proliferation of abnormal plasma cells. Global five-year survival rates range from 60% to 70%, largely due to novel therapeutic strategies. In our country, conventional therapies remain standard, with monoclonal antibodies recently introduced for relapsed/refractory cases....

By Dragana Drašković, Goran Marjanović, Miodrag Vučić, Irena Ćojbašić